News
ATHE
2.140
+6.47%
0.130
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Three posters were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado. The Company's work in Parkinson's disease and Multiple System Atrophy is described. Alterity Therapeutics is a biotechnology company dedicated to developing treatments for neurodegenerative diseases.
Benzinga · 1d ago
Alterity Therapeutics Showcases Promising Neurodegenerative Drug Data
TipRanks · 1d ago
Alterity Therapeutics Expands Securities Quotation
Alterity Therapeutics Limited announced the application for the quotation of additional securities. The company has issued options expiring on August 31, 2026. The move could potentially impact the company’s stock performance and investor interest. ATHE stock is down 2% in the last week.
TipRanks · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Dynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. Cardio Diagnostics Hldgs stock rose 14.28% and Aptorum Gr shares rose 12.61%. Poseida Therapeutics ( NASDAQ:PSTX) shares declined by 15.2% during the session.
Benzinga · 3d ago
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.
Benzinga · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Longeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday's regular session. Mobile-health Network shares rose 35.53% during the session. Jaguar Health and Organovo Holdings were the biggest gainers. Marinus Pharma and China SXT Pharmaceuticals were the largest losers.
Benzinga · 3d ago
NXPL, MGRM and OCX among pre-market losers
U.S. Economy NXPL, MGRM and OCX among pre-market losers. Marinus Pharmaceuticals -74% provides update on the phase 3 RAISE trial. NextPlat Corp -19% as FDA puts Phase 1 schizophrenia study on hold.
Seeking Alpha · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Soligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. Cartesian Therapeutics and Longeveron also moved upwards. Losers Marinus Pharma and PaxMedica stock decreased by more than 20%.
Benzinga · 3d ago
Weekly Report: what happened at ATHE last week (0408-0412)?
Weekly Report · 3d ago
Alterity Therapeutics Shareholders Approve Resolutions
TipRanks · 6d ago
ATUS, ATHE and GRFS among pre-market losers
On the Move ATUS, ATHE and GRFS among pre-market losers. Aptevo Therapeutics (APVO) -55% on pricing public offering. Carmax (KMX) -9% after Q4 earnings release. Altice USA, Inc. (ATUS) and Grifols SA (GRFS) in the red.
Seeking Alpha · 04/11 12:16
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
New data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA. Alterity Therapeutics is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases.
Barchart · 04/10 06:25
Weekly Report: what happened at ATHE last week (0401-0405)?
Weekly Report · 04/08 11:22
Weekly Report: what happened at ATHE last week (0325-0329)?
Weekly Report · 04/01 11:20
Alterity Therapeutics Secures $3.9M R&D Refund
TipRanks · 03/26 12:57
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Limited received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive Scheme. Alterity is a biotechnology company dedicated to developing treatments for neurodegenerative diseases.
Barchart · 03/26 09:25
Weekly Report: what happened at ATHE last week (0318-0322)?
Weekly Report · 03/25 11:23
Weekly Report: what happened at ATHE last week (0311-0315)?
Weekly Report · 03/18 11:21
Alterity Therapeutics Ltd: Report of foreign issuer
Press release · 03/15 12:23
Weekly Report: what happened at ATHE last week (0304-0308)?
Weekly Report · 03/11 11:17
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.